Brokers Set Expectations for KalVista Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for KalVista Pharmaceuticals in a report released on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz expects that the specialty pharmaceutical company will earn ($0.72) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($2.83) EPS.

KALV has been the topic of several other research reports. HC Wainwright upped their target price on KalVista Pharmaceuticals from $16.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $35.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, April 11th.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $11.50 on Thursday. KalVista Pharmaceuticals has a one year low of $7.21 and a one year high of $16.88. The stock’s 50-day moving average is $12.78 and its 200 day moving average is $11.24. The firm has a market cap of $485.19 million, a price-to-earnings ratio of -3.65 and a beta of 0.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.09).

Insider Activity

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 4,474 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was bought at an average cost of $14.74 per share, with a total value of $65,946.76. Following the completion of the transaction, the insider now owns 4,743,157 shares of the company’s stock, valued at approximately $69,914,134.18. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, major shareholder Venrock Healthcare Capital Par bought 4,474 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was acquired at an average cost of $14.74 per share, with a total value of $65,946.76. Following the completion of the transaction, the insider now directly owns 4,743,157 shares of the company’s stock, valued at approximately $69,914,134.18. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Edward P. Feener sold 28,288 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $14.07, for a total value of $398,012.16. Following the completion of the transaction, the insider now directly owns 62,157 shares of the company’s stock, valued at $874,548.99. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 207,227 shares of company stock worth $2,808,574 and have sold 75,978 shares worth $1,070,918. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. lifted its stake in KalVista Pharmaceuticals by 11.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after purchasing an additional 383,435 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of KalVista Pharmaceuticals by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,781,419 shares of the specialty pharmaceutical company’s stock worth $21,822,000 after buying an additional 48,930 shares during the period. BlackRock Inc. increased its holdings in KalVista Pharmaceuticals by 2.1% during the 3rd quarter. BlackRock Inc. now owns 1,706,148 shares of the specialty pharmaceutical company’s stock valued at $24,757,000 after purchasing an additional 34,653 shares during the period. FMR LLC increased its holdings in KalVista Pharmaceuticals by 37.2% during the 2nd quarter. FMR LLC now owns 1,132,442 shares of the specialty pharmaceutical company’s stock valued at $11,143,000 after purchasing an additional 307,092 shares during the period. Finally, Saturn V Capital Management LLC increased its holdings in KalVista Pharmaceuticals by 55.8% during the 1st quarter. Saturn V Capital Management LLC now owns 1,121,982 shares of the specialty pharmaceutical company’s stock valued at $8,819,000 after purchasing an additional 402,045 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.